Kodiak Sciences Inc KOD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:02 PM EDT
3.74UNCH (UNCH)
Volume
2,417
Close
3.74quote price arrow down-0.10 (-2.60%)
Volume
345,364
52 week range
1.37 - 9.80
Loading...
  • Open3.94
  • Day High4.03
  • Day Low3.72
  • Prev Close3.84
  • 52 Week High9.80
  • 52 Week High Date06/07/23
  • 52 Week Low1.37
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap196.481M
  • Shares Out52.53M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta2.47
  • YTD % Change23.03

KEY STATS

  • Open3.94
  • Day High4.03
  • Day Low3.72
  • Prev Close3.84
  • 52 Week High9.80
  • 52 Week High Date06/07/23
  • 52 Week Low1.37
  • 52 Week Low Date10/27/23
  • Market Cap196.481M
  • Shares Out52.53M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta2.47
  • YTD % Change23.03

RATIOS/PROFITABILITY

  • EPS (TTM)-4.97
  • P/E (TTM)-0.75
  • Fwd P/E (NTM)-0.84
  • EBITDA (TTM)-259.023M
  • ROE (TTM)-74.22%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kodiak Sciences Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high...
Victor Perlroth M.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
John Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Address
1200 PAGE MILL RD
Palo Alto, CA
94304
United States

Top Peers

SYMBOLLASTCHG%CHG
GALT
Galectin Therapeutics Inc
3.06+0.22+7.75%
TRVI
Trevi Therapeutics Inc
2.77-0.15-5.31%
ATOS
Atossa Therapeutics Inc
1.61+0.07+4.55%
LENZ
LENZ Therapeutics Inc
15.84+0.12+0.76%
INO
Inovio Pharmaceuticals Inc
13.07+1.65+14.45%